[1] |
Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4 related disease[J]. BMJ, 2020, 369:m1067.
|
[2] |
Zhou J, Peng Y, Peng L, et al. Serum IgE in the clinical features and disease outcomes of IgG4-related disease: A large retrospective cohort study[J]. Arthritis Res Ther, 2020, 22(1):255.
doi: 10.1186/s13075-020-02338-1
pmid: 33097076
|
[3] |
Gowthaman U, Chen JS, Zhang B, et al. Identification of a T follicular helper cell subset that drives anaphylactic IgE[J]. Science, 2019, 365(6456):eaaw6433.
|
[4] |
Borges T, Silva S. IgG4-related disease: How to place it in the spectrum of immune-mediated and rheumatologic disorders?[J]. Mod Rheumatol, 2020, 30(4):609-616.
doi: 10.1080/14397595.2019.1705537
pmid: 31852351
|
[5] |
Akiyama M, Yasuoka H, Yoshimoto K, et al. Interleukin-4 contributes to the shift of balance of IgG subclasses toward IgG4 in IgG4-related disease[J]. Cytokine, 2018, 110: 416-419.
doi: S1043-4666(18)30209-6
pmid: 29861381
|
[6] |
Yoon HK, Shim YS, Kim PH, et al. The TLR7 agonist imiquimod selectively inhibits IL-4-induced IgE production by suppressing IgG1/IgE class switching and germline ε transcription through the induction of BCL6 expression in B cells[J]. Cell Immunol, 2019, 338:1-8.
doi: 10.1016/j.cellimm.2019.02.006
URL
|
[7] |
Culver EL, Sadler R, Bateman AC, et al. Increases in IgE, eosinophils, and mast cells can be used in diagnosis and to predict relapse of IgG4-related disease[J]. Clin Gastroenterol Hepatol, 2017, 15(9):1444-1452.
doi: 10.1016/j.cgh.2017.02.007
URL
|
[8] |
Wang M, Zhang P, Lin W, et al. Differences and similarities between IgG4-related disease with and without dacryoadenitis and sialoadenitis: Clinical manifestations and treatment efficacy[J]. Arthritis Res Ther, 2019, 21(1):44.
doi: 10.1186/s13075-019-1828-8
pmid: 30709411
|
[9] |
Wang L, Zhang P, Zhang X, et al. Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease: A prospective study of 403 patients[J]. Rheumatology (Oxford), 2019, 58(5):820-830.
doi: 10.1093/rheumatology/key397
pmid: 30561747
|
[10] |
Wang L, Zhang P, Wang M, et al. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: A prospective study of 215 patients[J]. Arthritis Res Ther, 2018, 20(1):65.
doi: 10.1186/s13075-018-1567-2
pmid: 29636109
|
[11] |
Ming B, Zhong J, Dong L. Role of eosinophilia in IgG4-related disease[J]. Clin Exp Rheumatol, 2022, 40(5):1038-1044.
|
[12] |
张文, 董凌莉, 朱剑, 等. IgG-4相关性疾病诊治中国专家共识[J]. 中华内科杂志, 2021, 60(3):192-206.
|
[13] |
Khan S, Gordins P, Durairaj S. JAK inhibition as a therapeutic strategy for IgG4-RD[J]. J Investig Allergol Clin Immunol, 2021, 31(3):280-281.
doi: 10.18176/jiaci
URL
|
[14] |
Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases[J]. Nat Rev Drug Discov, 2017, 16(12):843-862.
doi: 10.1038/nrd.2017.201
pmid: 29104284
|
[15] |
Xia CS, Long Y, Liu Y, et al. IL-7 promotes the expansion of circulating CD28-cytotoxic T lymphocytes in patients with IgG4-related disease via the JAK signaling[J]. Front Immunol, 2022, 13:922307.
doi: 10.3389/fimmu.2022.922307
URL
|
[16] |
Lu H, Wu X, Peng Y, et al. TSLP promoting B cell proliferation and polarizing follicular helper T cell as a therapeutic target in IgG4-related disease[J]. J Transl Med, 2022, 20(1):414.
doi: 10.1186/s12967-022-03606-1
pmid: 36076269
|